These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34234994)

  • 1. Preclinical development and characterisation of
    Wong NC; Cai Y; Meszaros LK; Biersack HJ; Cook GJ; Ting HH; Mottaghy FM
    Am J Nucl Med Mol Imaging; 2021; 11(3):154-166. PubMed ID: 34234994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Phase I Study of a
    Xing Y; Chand G; Liu C; Cook GJR; O'Doherty J; Zhao L; Wong NCL; Meszaros LK; Ting HH; Zhao J
    J Nucl Med; 2019 Sep; 60(9):1213-1220. PubMed ID: 30796165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inter-rater and intra-rater agreement of [
    Hughes DJ; Chand G; Johnson J; Bailey D; Adamson K; Goh V; Cook GJR
    EJNMMI Res; 2023 May; 13(1):51. PubMed ID: 37256434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inter- and intraobserver agreement of the quantitative assessment of [
    Hughes DJ; Chand G; Goh V; Cook GJR
    EJNMMI Res; 2020 Dec; 10(1):145. PubMed ID: 33259032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Pretargeted Imaging Strategy for Immune Checkpoint Ligand PD-L1 Expression in Tumor Based on Bioorthogonal Diels-Alder Click Chemistry.
    Qiu L; Tan H; Lin Q; Si Z; Mao W; Wang T; Fu Z; Cheng D; Shi H
    Mol Imaging Biol; 2020 Aug; 22(4):842-853. PubMed ID: 31741201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasive Imaging of Tumor PD-L1 Expression Using [
    Zhang Y; Ding Y; Li N; Wang S; Zhou S; Li R; Yang H; Li W; Qu J
    Mol Pharm; 2023 Jan; 20(1):690-700. PubMed ID: 36541699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy.
    Gao H; Wu Y; Shi J; Zhang X; Liu T; Hu B; Jia B; Wan Y; Liu Z; Wang F
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive Evaluation of Tumoral PD-L1 Using a Novel
    Hu B; Ma X; Shi L; Liu T; Li L; Yao M; Li C; Jia B
    Mol Pharm; 2024 Apr; 21(4):1977-1986. PubMed ID: 38395797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and preliminary biological evaluation of a novel
    Zhu D; Xu X; Zou P; Liu Y; Wang H; Han G; Lu C; Xie M
    Bioorg Med Chem Lett; 2023 Nov; 96():129496. PubMed ID: 37797805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [
    Nazir MS; Hughes DJ; Chand G; Adamson K; Johnson J; Bailey D; Gibson V; Ting HH; Lyon AR; Cook GJR;
    EJNMMI Res; 2023 May; 13(1):44. PubMed ID: 37195370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel small
    Liang Z; Hu X; Hu H; Wang P; Cai J
    Front Oncol; 2022; 12():1017737. PubMed ID: 36387113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of
    Fan M; Yao J; Zhao Z; Zhang X; Lu J
    Pharmaceuticals (Basel); 2024 Jul; 17(7):. PubMed ID: 39065756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implication of
    Gao Y; Luo Q; Sun Z; Gao H; Yu Y; Sun Y; Ma X; Han C; Shi J; Wang F
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36858461
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Ferro-Flores G; Ocampo-García B; Cruz-Nova P; Luna-Gutiérrez M; Bravo-Villegas G; Azorín-Vega E; Jiménez-Mancilla N; Michel-Sánchez E; García-Pérez O; Lara-Almazán N; Santos-Cuevas C
    Pharmaceutics; 2023 Nov; 15(12):. PubMed ID: 38140003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of (99m)Tc-HYNIC-TMTP1 as a tumor-homing imaging agent targeting metastasis with SPECT.
    Li F; Cheng T; Dong Q; Wei R; Zhang Z; Luo D; Ma X; Wang S; Gao Q; Ma D; Zhu X; Xi L
    Nucl Med Biol; 2015 Mar; 42(3):256-62. PubMed ID: 25516099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of 99mTc-MIBI SPECT(/CT) to monitor multidrug resistance-related proteins and apoptosis-related proteins in patients with ovarian cancer: a preliminary study.
    Kurata S; Ushijima K; Kawahara A; Kaida H; Kawano K; Hirose Y; Kage M; Kamura T; Ishibashi M; Abe T
    Ann Nucl Med; 2015 Aug; 29(7):643-9. PubMed ID: 25921216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers.
    Broos K; Keyaerts M; Lecocq Q; Renmans D; Nguyen T; Escors D; Liston A; Raes G; Breckpot K; Devoogdt N
    Oncotarget; 2017 Jun; 8(26):41932-41946. PubMed ID: 28410210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of isostructural Tc-99m- and Re-188-folate-Gly-Gly-Cys-Glu for folate receptor-positive tumor targeting.
    Kim WH; Kim CG; Kim MH; Kim DW; Park CR; Park JY; Lee YS; Youn H; Kang KW; Jeong JM; Chung JK
    Ann Nucl Med; 2016 Jun; 30(5):369-79. PubMed ID: 26993818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigations of (99m)Tc-labeled glucarate as a SPECT radiotracer for non-small cell lung cancer (NSCLC) and potential tumor uptake mechanism.
    Meng L; Xiu Y; Li Y; Xu X; Li S; Li X; Pak KY; Shi H; Cheng D
    Nucl Med Biol; 2015 Jul; 42(7):608-13. PubMed ID: 25890861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.